LAURUSLABS.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 19:00):

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally...

Stats
本日の出来高	756 793
平均出来高	2.21M
時価総額	233.97B
EPS	INR0 ( 2024-04-24 )
次の収益日	( INR0 ) 2024-07-25
Last Dividend	INR1.200 ( 2023-05-10 )
Next Dividend	INR0 ( N/A )
P/E	146.66
ATR14	INR0.591 (0.14%)

ボリューム相関

長: -0.14 (neutral)

短: 0.38 (neutral)

Signal:(69.287) Neutral

Laurus Labs Limited 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Laurus Labs Limited 相関 - 通貨/商品

-0.16
( neutral )

-0.01
( neutral )

0.36
( neutral )

0.32
( neutral )

-0.53
( weak negative )

-0.82
( strong negative )

Laurus Labs Limited 財務諸表

Annual	2023
収益:	INR50.41B
総利益:	INR15.84B (31.42 %)
EPS:	INR2.98

FY	2023
収益:	INR50.41B
総利益:	INR15.84B (31.42 %)
EPS:	INR2.98

FY	2022
収益:	INR60.41B
総利益:	INR32.66B (54.07 %)
EPS:	INR14.69

FY	2022
収益:	INR48.89B
総利益:	INR26.40B (54.01 %)
EPS:	INR15.42

Financial Reports:

No articles found.

Laurus Labs Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0.800 (N/A)	INR0 (N/A)	INR1.200 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Laurus Labs Limited Dividend Information - Dividend Knight

Dividend Sustainability Score: 8.03 - good (80.33%) | Divividend Growth Potential Score: 5.86 - Stable (17.24%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.300	2017-07-06
Last Dividend	INR1.200	2023-05-10
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	INR7.40	--
Avg. Dividend % Per Year	0.35%	--
Score	3.35	--
Div. Sustainability Score	8.03
Div.Growth Potential Score	5.86
Div. Directional Score	6.95	--

Next Divdend (Est)
(2024-05-13)

INR1.329 Estimate 3.60 %

Dividend Stability

0.29 Very Poor

Dividend Score

3.35

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2017	INR0	0.00%
2018	INR0.300	0.30%
2019	INR0.300	0.39%
2020	INR1.300	1.77%
2021	INR2.00	0.57%
2022	INR2.00	0.38%
2023	INR1.200	0.32%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TTKPRESTIG.NS	Dividend Junior	2023-07-21	Annually	20	0.43%
PLASTIBLEN.NS	Dividend Knight	2023-06-23	Annually	18	1.26%
JKTYRE.NS	Dividend Junior	2023-07-27	Annually	17	0.91%
DIAMONDYD.NS	Dividend Junior	2023-07-27	Annually	7	0.06%
360ONE.NS	Dividend Knight	2023-07-28	Semi-Annually	6	2.85%
SOMANYCERA.NS	Dividend Junior	2023-08-18	Annually	23	0.39%
MOIL.NS	Dividend Knight	2023-09-08	Semi-Annually	14	2.38%
HDFCBANK.NS	Dividend Junior	2023-05-16	Annually	28	0.58%
BHANDARI.NS	Dividend Junior	2023-09-22	Annually	8	0.18%
RAJRATAN.NS	Dividend Junior	2023-07-27	Annually	4	0.12%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0318	1.500	9.36	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0191	1.200	9.36	10.00	[0 - 0.3]
returnOnEquityTTM	0.0396	1.500	-0.672	-1.007	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.232	0.800	8.84	7.07	[1 - 3]
quickRatioTTM	0.584	0.800	-1.272	-1.017	[0.8 - 2.5]
cashRatioTTM	0.0455	1.500	-0.858	-1.287	[0.2 - 2]
debtRatioTTM	0.300	-1.500	5.00	-7.50	[0 - 0.6]
interestCoverageTTM	2.19	1.000	-0.300	-0.300	[3 - 30]
operatingCashFlowPerShareTTM	10.46	2.00	6.51	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.46	2.00	4.77	9.54	[0 - 20]
debtEquityRatioTTM	0.612	-1.500	7.55	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.465	1.000	5.58	5.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.0795	1.000	-0.410	-0.410	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.224	1.000	9.86	9.86	[0.2 - 2]
assetTurnoverTTM	0.601	0.800	9.33	7.46	[0.5 - 2]
Total Score				8.03

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	145.17	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0396	2.50	-0.432	-1.007	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.46	2.00	6.51	9.54	[0 - 30]
dividendYielPercentageTTM	0.556	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.46	2.00	6.51	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.512	1.500	9.92	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.112	1.000	9.70	0	[0.1 - 0.5]
Total Score				5.86

Laurus Labs Limited

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.